Cargando…

Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis

BACKGROUND/AIMS: In a recent study, attenuation imaging (ATI) with ultrasound was used as a new approach for detecting liver steatosis. However, although there are many studies on ATI and controlled attenuation parameter (CAP) that prove their practicability, there are few studies comparing these tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Po-Ke, Wu, Li-Sha, Su, Wei-Wen, Su, Pei-Yuan, Chen, Yang-Yuan, Hsu, Yu-Chun, Yen, Hsu-Heng, Wu, Chia-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519468/
https://www.ncbi.nlm.nih.gov/pubmed/34653177
http://dx.doi.org/10.1371/journal.pone.0254892
_version_ 1784584456610250752
author Hsu, Po-Ke
Wu, Li-Sha
Su, Wei-Wen
Su, Pei-Yuan
Chen, Yang-Yuan
Hsu, Yu-Chun
Yen, Hsu-Heng
Wu, Chia-Lin
author_facet Hsu, Po-Ke
Wu, Li-Sha
Su, Wei-Wen
Su, Pei-Yuan
Chen, Yang-Yuan
Hsu, Yu-Chun
Yen, Hsu-Heng
Wu, Chia-Lin
author_sort Hsu, Po-Ke
collection PubMed
description BACKGROUND/AIMS: In a recent study, attenuation imaging (ATI) with ultrasound was used as a new approach for detecting liver steatosis. However, although there are many studies on ATI and controlled attenuation parameter (CAP) that prove their practicability, there are few studies comparing these two methods. As such, this study compared CAP and ATI for the detection and evaluation of liver steatosis. METHODS: A prospective analysis of 28 chronic liver disease patients who underwent liver biopsy, FibroScan® imaging, and ATI with ultrasound was conducted. The presence and degree of steatosis, as measured with the FibroScan® device and ATI, were compared with the pathological results obtained using liver biopsy. RESULTS: The areas under the receiver operating characteristic curve (AUROC) of ATI and CAP for differentiating between normal and hepatic steatosis were 0.97 (95% confidence interval [CI] 0.83–1.00) and 0.96 (95% CI 0.81–0.99), respectively. ATI has a higher AUROC than CAP does in liver steatosis, at 0.99 (95% CI, 0.86–1.00) versus 0.91 (95% CI, 0.74–0.98) in grade ≥ 2 and 0.97 (95% CI, 0.82–1.00) versus 0.88 (95% CI, 0.70–0.97) in grade = 3, respectively. CONCLUSION: The ATI and CAP results showed good consistency and accuracy for the steatosis grading when compared with the liver biopsy results. Moreover, ATI is even better than CAP in patients with moderate or severe steatosis. Therefore, ATI represents a non-invasive and novel diagnostic tool with which to support the diagnosis of liver steatosis in clinical practice.
format Online
Article
Text
id pubmed-8519468
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85194682021-10-16 Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis Hsu, Po-Ke Wu, Li-Sha Su, Wei-Wen Su, Pei-Yuan Chen, Yang-Yuan Hsu, Yu-Chun Yen, Hsu-Heng Wu, Chia-Lin PLoS One Research Article BACKGROUND/AIMS: In a recent study, attenuation imaging (ATI) with ultrasound was used as a new approach for detecting liver steatosis. However, although there are many studies on ATI and controlled attenuation parameter (CAP) that prove their practicability, there are few studies comparing these two methods. As such, this study compared CAP and ATI for the detection and evaluation of liver steatosis. METHODS: A prospective analysis of 28 chronic liver disease patients who underwent liver biopsy, FibroScan® imaging, and ATI with ultrasound was conducted. The presence and degree of steatosis, as measured with the FibroScan® device and ATI, were compared with the pathological results obtained using liver biopsy. RESULTS: The areas under the receiver operating characteristic curve (AUROC) of ATI and CAP for differentiating between normal and hepatic steatosis were 0.97 (95% confidence interval [CI] 0.83–1.00) and 0.96 (95% CI 0.81–0.99), respectively. ATI has a higher AUROC than CAP does in liver steatosis, at 0.99 (95% CI, 0.86–1.00) versus 0.91 (95% CI, 0.74–0.98) in grade ≥ 2 and 0.97 (95% CI, 0.82–1.00) versus 0.88 (95% CI, 0.70–0.97) in grade = 3, respectively. CONCLUSION: The ATI and CAP results showed good consistency and accuracy for the steatosis grading when compared with the liver biopsy results. Moreover, ATI is even better than CAP in patients with moderate or severe steatosis. Therefore, ATI represents a non-invasive and novel diagnostic tool with which to support the diagnosis of liver steatosis in clinical practice. Public Library of Science 2021-10-15 /pmc/articles/PMC8519468/ /pubmed/34653177 http://dx.doi.org/10.1371/journal.pone.0254892 Text en © 2021 Hsu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hsu, Po-Ke
Wu, Li-Sha
Su, Wei-Wen
Su, Pei-Yuan
Chen, Yang-Yuan
Hsu, Yu-Chun
Yen, Hsu-Heng
Wu, Chia-Lin
Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
title Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
title_full Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
title_fullStr Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
title_full_unstemmed Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
title_short Comparing the controlled attenuation parameter using FibroScan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
title_sort comparing the controlled attenuation parameter using fibroscan and attenuation imaging with ultrasound as a novel measurement for liver steatosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519468/
https://www.ncbi.nlm.nih.gov/pubmed/34653177
http://dx.doi.org/10.1371/journal.pone.0254892
work_keys_str_mv AT hsupoke comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT wulisha comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT suweiwen comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT supeiyuan comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT chenyangyuan comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT hsuyuchun comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT yenhsuheng comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis
AT wuchialin comparingthecontrolledattenuationparameterusingfibroscanandattenuationimagingwithultrasoundasanovelmeasurementforliversteatosis